Part 3.1 / M1, M8, M11
3. PART 3: HARMONISED CLASSIFICATION AND LABELLING TABLE
|
Index No |
►M18 Chemical name ◄ |
EC No |
CAS No |
Classification |
Labelling |
Notes |
||||
|
Hazard Class and Category Code(s) |
Hazard statement Code(s) |
Pictogram, Signal Word Code(s) |
Hazard statement Code(s) |
Suppl. Hazard statement Code(s) |
||||||
|
015-003-00-2 |
calcium phosphide; tricalcium diphosphide |
215-142-0 |
Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 |
H260 H300 H311 H330 H318 H400 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H260 H300 H311 H330 H318 H400 |
EUH029 EUH032 |
M = 100 |
|
|
|
019-003-00-3 |
potassium (E,E)-hexa-2,4-dienoate |
246-376-1 |
Eye Irrit. 2 |
H319 |
GSH07 Wng |
H319 |
|
|
|
|
|
031-001-00-4 |
gallium arsenide |
215-114-8 |
Repr. 1B Carc. 1B STOT RE 1 |
H360F H350 H372 (respiratory and haematopoietic systems) |
GHS08 Dgr |
H360F H350 H372 (respiratory and haematopoietic systems) |
|
|
|
|
|
050-008-00-3 |
tributyltin compounds, with the exception of those specified elsewhere in this annex |
— |
— |
Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H360FD H301 H312 H372** H315 H319 H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360FD H301 H312 H372** H315 H319 H410 |
|
* STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 |
A 1 |
|
603-102-00-9 |
1,2-epoxybutane |
203-438-2 |
Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 |
H225 H351 H302 H312 H332 H335 H315 H319 |
GHS02 GHS08 GHS07 Dgr |
H225 H351 H302 H312 H332 H335 H315 H319 |
|
|
|
|
|
603-197-00-7 |
tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol |
403-640-2 |
Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H361d*** H302 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d*** H302 H410 |
|
M = 1 M = 10 |
|
|
|
606-054-00-7 |
isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone |
— |
Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H361d*** H400 H410 |
GHS08 GHS09 Wng |
H361d*** H410 |
|
M = 10 M = 100 |
|
|
|
606-148-00-8 |
carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] |
202-759-5 [1] 218-827-2 [2] 229-352-5 [3] |
99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
606-149-00-3 |
tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione |
— |
Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d H373 (eyes, kidneys, liver) H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d H373 (eyes, kidneys, liver) H317 H410 |
|
M = 100 M = 10 |
|
|
|
607-197-00-8 |
nonanoic acid |
203-931-2 |
Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 |
H315 H319 H412 |
GHS07 Wng |
H315 H319 H412 |
|
|
|
|
|
607-707-00-9 |
fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate |
— |
STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 (kidneys) H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 (kidneys) H317 H410 |
|
M = 1 M = 1 |
|
|
|
607-708-00-4 |
octanoic acid |
204-677-5 |
Skin Corr. 1C Aquatic Chronic 3 |
H314 H412 |
GHS05 Dgr |
H314 H412 |
|
|
|
|
|
607-709-00-X |
decanoic acid |
206-376-4 |
Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 |
H315 H319 H412 |
GHS07 Wng |
H315 H319 H412 |
|
|
|
|
|
607-710-00-5 |
1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear |
271-093-5 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
|
|
|
|
607-711-00-0 |
spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate |
— |
Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H361fd H335 H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361fd H335 H319 H317 H410 |
|
M = 1 M = 1 |
|
|
|
607-712-00-6 |
dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate |
250-778-2 |
Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 |
H361d H373 (liver) H314 H317 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H361d H373 (liver) H314 H317 H410 |
EUH071 |
M = 1 |
|
|
|
607-713-00-1 |
fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate |
— |
Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H301 H330 H317 H400 H410 |
GHS06 GHS09 Dgr |
H301 H330 H317 H410 |
|
M = 100 M = 1 000 |
|
|
|
607-714-00-7 |
triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate |
— |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 100 M = 10 |
|
|
|
607-715-00-2 |
bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate |
442-820-5 |
STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 H317 H410 |
|
M = 1 M = 1 |
|
|
|
613-042-00-5 |
imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole |
252-615-0 |
Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 |
H351 H301 H332 H318 H410 |
GHS08 GHS06 GHS05 GHS09 Dgr |
H351 H301 H332 H318 H410 |
|
M = 10 |
|
|
|
613-057-00-7 |
dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine |
216-474-9 |
Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H361d H373 (liver) H314 H317 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H361d H373 (liver) H314 H317 H410 |
EUH071 |
M = 1 M = 1 |
|
|
|
613-133-00-X |
etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole |
219-991-8 |
Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H317 H410 |
|
M = 1 M = 1 |
|
|
|
613-149-00-7 |
pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one |
405-700-3 |
Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
M = 1 000 M = 1 000 |
|
|
|
613-319-00-0 |
imidazole |
206-019-2 |
Repr. 1B Acute Tox. 4 Skin Corr. 1C |
H360D H302 H314 |
GHS08 GHS07 GHS05 Dgr |
H360D H302 H314 |
|
|
|
|
|
613-320-00-6 |
lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione |
218-499-0 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 10 M = 10 |
|
|
|
616-213-00-2 |
mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 M = 1 |
|
|
|
616-214-00-8 |
metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide |
— |
Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H373 (eyes, kidneys) H400 H410 |
GHS08 GHS09 Wng |
H351 H373 (eyes, kidneys) H410 |
|
M = 1 000 M = 100 |
|
|
|
616-215-00-3 |
dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide |
— |
Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
M = 10 M = 10 |
|
|
|
616-216-00-9 |
flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide |
— |
Acute Tox. 4 |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
|
616-217-00-4 |
sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide |
— |
Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M = 1 M = 1 |
|
|